3 Largest Passenger Car Maker, Branded Formulations Company and Mid Income Housing Developer Stocks With a Strong Future Roadmap: Maruti Suzuki, Eris Lifesciences and Ashiana Housing
- November 5, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Maruti Suzuki, Eris Lifesciences and Ashiana Housing: ROE of 13.6% to 15.9% and FY22 to FY26 revenue CAGR of 20.1% to 50.2%. Prices as of 4 Nov 2026.
Quick Answer
The three car maker, branded drug and housing stocks to watch are Maruti Suzuki, Eris Lifesciences and Ashiana Housing. Their return on equity ranges from 13.6% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 20.1% to 50.2%. Eris Lifesciences has the highest return on equity at 15.9%, while Ashiana Housing has the fastest revenue growth at 50.2% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Car maker, branded drug and housing stocks let investors follow companies that serve a growing part of the Indian economy. Maruti Suzuki, Eris Lifesciences and Ashiana Housing cover the largest passenger car maker, a branded formulations company and a mid income housing developer.
This list covers three car maker, branded drug and housing stocks with complete current figures: Maruti Suzuki, Eris Lifesciences and Ashiana Housing. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Car Maker, Branded Drug and Housing Stocks?
Car maker, branded drug and housing stocks are listed companies that sell hatchbacks, sedans and utility vehicles through a vast network, market branded formulations in chronic and acute care, and develop mid-income residential projects and senior living communities. Their earnings depend on car demand, prescriptions and home sales.
Car Maker, Branded Drug and Housing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Maruti Suzuki | 11,995 | 353,984 | 24.7 | 23.4 | 13.7 | 0.00 |
| Eris Lifesciences | 1,215 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
| Ashiana Housing | 370 | 3,586 | 30.3 | 30.7 | 13.6 | 0.35 |
On valuation, Eris Lifesciences and Ashiana Housing trade at a P/E below the industry P/E, while Maruti Suzuki trades above it, which reflects the growth the market already expects. Readers comparing car maker, branded drug and housing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Car Maker, Branded Drug and Housing Stocks Have a Strong Roadmap in India?
Car maker, branded drug and housing stocks have a strong roadmap in India because a healthy car market, steady demand for branded medicines and growing mid-income housing demand keep widening the market for these companies.
- Cars. A wide network supports steady sales.
- Branded drugs. Doctors prescribe trusted brands.
- Housing. Mid income families seek new homes.
Why Maruti Suzuki Features Among These Car Maker, Branded Drug and Housing Stocks
Among the car maker, branded drug and housing stocks on this list, Maruti Suzuki is India’s largest passenger car maker, selling a wide range of hatchbacks, sedans and utility vehicles through a vast sales and service network, and it also exports cars to many countries.
In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%.
Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P/E of 24.7, above the industry P/E of 23.4.
Roadmap: The company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.
What to watch: Follow monthly sales, utility vehicle mix, export volumes and progress on electric models.
Why Eris Lifesciences Features Among These Car Maker, Branded Drug and Housing Stocks
Among the auto, pharma and real estate shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Why Ashiana Housing Features Among These Car Maker, Branded Drug and Housing Stocks
Among the three companies on this list, Ashiana Housing develops mid-income residential projects and senior living communities in cities such as the Delhi region, Jaipur and Chennai. It is known for its focus on construction quality and timely delivery.
Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%.
The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7.
Roadmap: The company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.
What to watch: Track sales bookings, project launches and deliveries.
Maruti Suzuki vs Eris Lifesciences vs Ashiana Housing on Key Financials
The table below sets the three car maker, branded drug and housing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Maruti Suzuki | 90,074 | 187,673 | 20.1% | 14,680 | 7.8% |
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
| Ashiana Housing | 234 | 1,187 | 50.2% | 118 | 9.9% |
Eris Lifesciences posts the highest return on equity in this group at 15.9%. Maruti Suzuki has the largest FY26 revenue at Rs 187,673 crore, and Ashiana Housing shows the fastest revenue growth with a 50.2% compound annual rate. A useful habit with car maker, branded drug and housing stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Car Maker, Branded Drug and Housing Stocks
Every theme carries risks that deserve a check before any decision. For these car maker, branded drug and housing stocks, the main points are: Long-term auto, pharma and real estate shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Production cycles. Vehicle output can vary with demand.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter car maker, branded drug and housing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Car Maker, Branded Drug and Housing Stocks
Car maker, branded drug and housing stocks reward investors who follow demand trends, order books and margins together. Maruti Suzuki, Eris Lifesciences and Ashiana Housing each have a clear plan to grow. Based on the 4 November 2026 close, Maruti Suzuki trades at Rs 11,995, Eris Lifesciences at Rs 1,215 and Ashiana Housing at Rs 370. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these car maker, branded drug and housing stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track car maker, branded drug and housing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are car maker, branded drug and housing stocks?
Ans. Car maker, branded drug and housing stocks are listed companies that sell hatchbacks, sedans and utility vehicles through a vast network, market branded formulations in chronic and acute care, and develop mid-income residential projects and senior living communities. Their earnings depend on car demand, prescriptions and home sales. This list looks at three of them, Maruti Suzuki, Eris Lifesciences and Ashiana Housing, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which car maker, branded drug and housing stocks are covered in this list?
Ans. This list covers Maruti Suzuki, Eris Lifesciences and Ashiana Housing. Based on the 4 November 2026 close, Maruti Suzuki traded at Rs 11,995, Eris Lifesciences at Rs 1,215 and Ashiana Housing at Rs 370. Their return on equity ranges from 13.6% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 20.1% to 50.2%.
Why do car maker, branded drug and housing stocks have a strong future roadmap in India?
Ans. Car maker, branded drug and housing stocks have a strong roadmap in India because a healthy car market, steady demand for branded medicines and growing mid-income housing demand keep widening the market for these companies. The main drivers are as follows. Cars. A wide network supports steady sales. Branded drugs. Doctors prescribe trusted brands. Housing. Mid income families seek new homes. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Maruti Suzuki performed financially?
Ans. Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%. In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P/E of 24.7, above the industry P/E of 23.4. Looking ahead, the company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
How has Ashiana Housing performed financially?
Ans. Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7. Looking ahead, the company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.
What risks should investors check before buying car maker, branded drug and housing stocks?
Ans. Investors should check a few risks before buying car maker, branded drug and housing stocks. Production cycles. Vehicle output can vary with demand. Housing cycles. Real estate and building demand can vary with rates and sentiment. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of car maker, branded drug and housing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
